On Monday we learnt from Sir Patrick Vallance, the federal government’s Chief Scientific Adviser that Coronavirus will likely never disappear plus a vaccine won’t stop it completely. He also said that ministers and experts should stop ‘over-promising’ and turn into realistic concerning the prospects of any vaccine and also the likely timeline of merely one, unlikely before spring next season.
He then echoed his earlier warnings and people of his colleague Professor Chris Whitty which the COVID-19 fight is a long one, and it’ll be with us for great.
So, with this should we assume there is absolutely no ‘silver bullet’ for COVID-19 infections?
What if there have been a single treatment that:
could stop the issue in its tracks, was anti-inflammatory; money immune system's response to chlamydia and stopping it from overreacting dangerously, in instances when patients developed secondary microbial infection in the lungs could supercharge antibiotics; boosting their efficacy and eve, was a repurposed drug; already proven as safe was all to easy to make, scalable for the level forced to make a difference within the pandemic and was cost-effective, then wouldn't that be something we need to all be anticipating?
Surely though no such ‘silver bullet’ game changing therapy exists? After all, really the only treatments we learn about for COVID are the type which President Trump took, that have been either very new, expensive and experimental or possess a narrow application to a particular aspect of the disease.
Well, you heard it here first – this type of ‘silver bullet’ treatment does exist today. It’s called Nylexa®, through the small UK biotech company NovaBiotics Ltd. It’s substances have been safely employed in medicines that treat unrelated conditions for more than 30 years.
NovaBiotics discovered Nylexa’s potential benefits in COVID-19 after a decade of research in challenging to treat, drug-resistant infections, such as complex chest infections and inflammation regarding cystic fibrosis (CF) lung disease. In March they sent applications for a £1m grant from Innovate UK (representing the us govenment) to begin clinical studies. That grant was eventually awarded recently, and also the government are considering getting in touch with include Nylexa on two separate NHS platform studies.
But why, I hear you may well ask, if it is so good have we not heard of it before? Why are the government plus the press not shouting about this on the rooftops? Why is this not being demanded by clinicians in need of effective control of their patients?
I’m afraid to convey, everything boils down to money. Small biotech companies find it tricky to get attention while they don’t have the resources accessible to their larger better funded rivals. The names we learned about regularly in terms of ground breaking new remedies are invariably large multi-national pharmaceutical companies with deep pockets and big budgets in promoting their own particular wares. They make sure their drugs obtain the required attention. NovaBiotics is really a small private company funded using a group of loyal and supportive shareholders so unfortunately not have the resources to compete for attention together with the big boys.
Which is the reason this situation can be so frustrating. In mitigating the consequences of contracting COVID-19, Nylexa® could increase public confidence of living using the virus for your longer term and potentially allow a much better degree of normality revisit the way in which we live, benefiting the economy directly besides easing COVID-19’s burden about the NHS and healthcare systems globally. Yet getting people in positions of influence to look at notice amongst every one of the others competing for his or her attention is quite difficult indeed.
It is reported that you have thousands of potential COVID-19 treatments in numerous studies across the world. I would challenge you to definitely show me the one that has the same possibility of positive impact as Nylexa®, yet this may not be currently portion of any trial, despite its impeccable credentials. So seriously UK Government, and ministers, get the finger out and acquire this drug into trials immediately. The sooner it gets tested, the earlier it can be used that can help sort out the mess the pandemic is mainly responsible for to all our everyday life.
About NovaBiotics Ltd
NovaBiotics Ltd can be a clinical-stage biotechnology company focused about the design and growth and development of first-in-class therapies for difficult-to-treat, medically unmet infectiousdiseases due to bacteria and fungi and respiratory conditions including cystic fibrosis and COVID-19.
A leading innovator inside the anti-infectives space, the Company’s robust technology and enterprize model has been validated through successful development, from concept to late stage clinical development, of the company’s most advanced product candidates. In addition to the lead Nylexa® programme along with the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a strong pipeline of earlier stage, high-value drug candidates including NP339 (Department of Health and Social Care funded programme) forever threatening, drug resistant invasive fungal disease and NP432 for multi- drug resistant microbial infection.
Nylexa® can be a novel, dual antimicrobial-immunomodulatory candidate therapy. It is often a simple, small molecule that’s broad ranging antimicrobial effects through directly targeting microbes and as well modulating the male body’s ability to control infection. Importantly, Nylexa’s active component has a key role from the resolution of infection and power over inflammation which NovaBiotics has exploited as being a solution to COVID-19.
For microbial infection, Nylexa is often a potential answer to a public health challenge even bigger than COVID-19: the worsening antimicrobial biotic resistance (AMR) crisis. Because Nylexa’s component is repurposed and has now been employed in medicines for other, unrelated conditions for more than many years, it may potentially be introduced into clinical practice inside a much shorter timescale than new antibiotic(s) treatments developed from first principle. Put simply, Nylexa® ‘supercharges’ existing antibiotics in microbial infection, especially against drug resistant bacteria.